A clinical-stage oncology compound selectively targets drug-resistant cancers
Kaitlin Long(Stanford University), Jason M. Sheltzer(Yale University), Olaf Klingbeil(Cold Spring Harbor Laboratory), Christopher R. Vakoc(Cold Spring Harbor Laboratory), Patrick L. Holland(Yale University), Simon Suhr(Yale University), Kristen M. John(Cold Spring Harbor Laboratory), Erin L. Sausville(Cold Spring Harbor Laboratory), Brandon Q. Mercado(Yale University), Uditi Bhatt(University Hospital Zurich), Linda Julian(Yale University), Allen C. Gao(UC Davis Comprehensive Cancer Center), Sara Ricardo(Cold Spring Harbor Laboratory), Stephen S. Taylor(Manchester Academic Health Science Centre), Steven M. Corsello(Cancer Prevention Institute of California), L. Romero(Yale University), Sarah L. Thompson(Yale University), Debanjan Bhattacharjee(Indian Institute of Chemical Technology), Beat Bornhäuser(University Children's Hospital Zurich), Samuel H. Newman-Stonebraker(Yale University), Anthony Tighe(Manchester Academic Health Science Centre)
Cited by 0
Related Papers
Copper induces cell death by targeting lipoylated TCA cycle proteins
|Science|2022|4.6k
Discovering the anticancer potential of non-oncology drugs by systematic viability profiling
|Nature Cancer|2020|880
Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated <i>Myc</i> regulation
|Genes & Development|2013|458
Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1–C-Mad2 core complex
|The Journal of Cell Biology|2010|333